|Day's Range||77.020 - 78.360|
|52 Week Range||64.180 - 86.720|
|PE Ratio (TTM)||37.71|
|Dividend & Yield||2.08 (2.70%)|
|1y Target Est||N/A|
Novo Nordisk stock popped Tuesday after AstraZeneca said its Type 2 diabetes drug didn't reduce the risk of cardiovascular events in a trial.
Certain pharma stocks have significant upside potential.
A leading competitor's osteoporosis drug encountered serious side effects in a late stage trial.